Utang jangka cendhak marang modal: ARCA Biopharma, Inc. (ABIO)

This daily price chart for ARCA Biopharma (ABIO) illustrates the debt-to-equity ratio, which stands at 0.00. The company's revenues depend on the implementation of Gencaro therapy for atrial fibrillation. Market capitalization relies on the development of niche drugs and the sale of licenses to medical centers. The business is currently undergoing an asset consolidation phase, resulting in operational activity being limited to minimal legal status expenditures.

The current liabilities-to-equity ratio measures a business's ability to cover current debts with net assets, determining the balance between default risk and the use of financial leverage. By analyzing changes in short-term debt relative to equity, an investor assesses the liquidity of ARCA Biopharma (ABIO), which is critical for sustaining the development of targeted cardiovascular drugs amid years of demand inertia for cardiac therapy.